Patents by Inventor Nick Mark Devoogdt

Nick Mark Devoogdt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
    Patent number: 11243214
    Abstract: The present invention is directed to the identification of a biomarker specifically located in the plasma membrane of pancreatic beta cells. Based on a set of specific features the biomarker is a unique candidate for imaging and targeting strategies to study the pancreatic beta cell mass in health and disease (T1D, T2D, pancreatic cancers, obesity, islet transplantation, beta cell regeneration).
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: February 8, 2022
    Assignees: UNIVERSITÉ LIBRE DE BRUXELLES, VRIJE UNIVERSITES BRUSSEL
    Inventors: Eizirik Decio Laks, Alexander Balhuizen, Nick Mark Devoogdt, Sam Marc Kris Aimé Massa, Luc Bouwens, Iris Mathijs
  • A NEW BIOMARKER EXPRESSED IN PANCREATIC BETA CELLS USEFUL IN IMAGING OR TARGETING BETA CELLS
    Publication number: 20190145987
    Abstract: The present invention is directed to the identification of a biomarker specifically located in the plasma membrane of pancreatic beta cells. Based on a set of specific features the biomarker is a unique candidate for imaging and targeting strategies to study the pancreatic beta cell mass in health and disease (T1D, T2D, pancreatic cancers, obesity, islet transplantation, beta cell regeneration).
    Type: Application
    Filed: April 21, 2017
    Publication date: May 16, 2019
    Inventors: Eizirik Decio LAKS, Alexander BALHUIZEN, Nick Mark DEVOOGDT, Sam Marc Kris Aimé MASSA, Luc BOUWENS, Iris MATHIJS
  • CX3CR1-targeting imaging agents and their use in the diagnosis and treatment of disease
    Patent number: 9637542
    Abstract: The present invention relates to CX3CR1-targeting imaging agents and their use in treatment and diagnosis of diseases. Single domain CX3CR1-targeting polypeptides linked to detection labels and their use in in vivo imaging of atherosclerotic plaques are described. The CX3CR1-targeting imaging agents are useful in the treatment and diagnosis of CX3CR1-mediated diseases including atherosclerosis.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: May 2, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Alisa K. Waterman, Nick Mark Devoogdt, Tony Lahoutte, Matthias Schneider, Sanjaya Singh, Cedric Jozef Néotère Ververken
  • CX3CR1-TARGETING IMAGING AGENTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF DISEASE
    Publication number: 20150056133
    Abstract: The present invention relates to CX3CR1-targeting imaging agents and their use in treatment and diagnosis of diseases. Single domain CX3CR1-targeting polypeptides linked to detection labels and their use in in vivo imaging of atherosclerotic plaques are described. The CX3CR1-targeting imaging agents are useful in the treatment and diagnosis of CX3CR1-mediated diseases including atherosclerosis.
    Type: Application
    Filed: August 20, 2014
    Publication date: February 26, 2015
    Inventors: Alisa K. WATERMAN, Nick Mark Devoogdt, Tony Lahoutte, Matthias SCHNEIDER, Sanjaya SINGH, Cedric Jozef Néotère VERVERKEN